[Unrelated HLA-matched donor marrow transplantation for one case of myelodysplastic syndrome].
To explore feasibility and efficacy of unrelated HLA matched donor marrow transplantation in treatment of myelodysplastic syndrome, one case (male, 31 years old) of myelodysplastic syndrome-refractory cytopenia with multilineage dysplasia (MDS-RCMD) has been received unrelated HLA-matched donor transplantation. Busulfan, cyclophosphamide, Ara-C, MeCCNU and antithymocyte globulin (ATG) were used for preparative regimen. Mycophenolate mofetile, cyclosporin A and short-term methotrexate were used for graft-versus-host disease prophylaxis. The results showed that neutrophil of > 0.5 x 10(9)/L, platelet of 58 x 10(9)/L and hemoglobin of 114 g/L were observed at 10, 20 days and 3 months respectively post transplantation. Disease-free survival without GVHD was 9 months. In conclusion, unrelated HLA matched donor marrow transplantation is an effective approach for treatment of patients with MDS.
Gao
Chun-Ji
CJ
Department of Hematology, General Hospital PLA, Beijing 100853, China. gaochunji@hotmail.com
Da
Wan-Ming
WM
Zhang
Bo-Long
BL
Han
Xiao-Ping
XP
Zhu
Hai-Yan
HY
Jin
Hai-Jie
HJ
Jing
Yu
Y
Huang
Wen-Rong
WR
D000328:Adult; D016026:Bone Marrow Transplantation; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000209:etiology; D006410:Hematopoiesis; D006650:Histocompatibility Testing; D006801:Humans; D008297:Male; D009190:Myelodysplastic Syndromes / Q000628:therapy*